To evaluate the association between the presence of CD8 and CD45RO T lymphocytes in bone marrow (BM), disseminated tumor cells (DTCs), tumor hypoxia and their impact on disease outcome. Material and methods: 91 naïve gastric cancer (GC) patients were enrolled into the study. DTCs, CD8-and CD45RO-positive T lymphocytes in BM were detected using immunocytochemistry. All patients were thoroughly informed about the study that was approved by the local ethics committee. Statistical analyses were done using NCSS2000/PASS2000 and Prism, version 4.03 software packages. 
It is known that tumor cells may be found in the bone marrow (BM) of patients with a variety of malignant tumors categorized as M 0 category [1] [2] [3] . The tumor cells in BM were named disseminated tumor cells (DTCs) [4] . It was shown that persistence of DTCs in BM is an independent prognostic factor for unfavorable disease outcome [2, 5, 6] . Moreover, there are data that DTCs may persist in the organism within long time without manifestation of disease [5, [7] [8] [9] [10] . Such state is known as tumor dormancy that is very intensively studied in many laboratories and clinics [10] [11] [12] [13] [14] . Interestingly, that it was suggested some years ago that BM and lymph nodes are privileged sites where tumor cells are controlled in a dormant state by the immune system [15] . Shen et al. [16] mentioned about interesting observation that DTCs derived from a variety of epithelial tumors seem to have a propensity to home to BM, including tumors which do not commonly form bone metastasis, such as colon cancer. This implies that BM might be a reservoir for DTCs from where they may recirculate into circulating system and then colonize in other distant organs. It has been shown that DTCs resist to chemotherapy and hormonal therapy, and survive in BM for years to decades. DTCs are dormant. Dormancy is related to cytostatic drug resistance and may be a pro perty of minimal residual disease and tumor stem cells.
One of the main problems is a question about mechanisms that can control the long-term persistence of DTCs in BM before the relapse or metastasis. The answer on this question could help to develop the methods to control the tumor dormancy, predict relapse of disease and propose the adequate therapy. In this context there are very important data about the participation of memory T cells occupied BM in the control of tumor dormancy. Farrar et al. [17] have used the murine B cell lymphoma (BCL 1 ) as a model of tumor dormancy in mice vaccinated with the BCP1 Ig and demonstrated that CD8-positive, but not CD4-positive, T cells are required for the maintenance of dormancy in BCL1 Ig-immunized BALB/c. Authors suggested that CD8-positive T cells via endo genous production of IFN-γ in collaboration with humoral immunity can induce and maintain the tumor dormancy. Feuerer et al. [18] have shown that breast cancer patients with DTCs in their BM had more memory CD4 T cells and more CD56 + CD8
+ cells than patients with tumor cell-negative BM. Taking into account obtained results authors hypothesized that "BM is a special compartment for immunological memory and tumor dormancy". Later these authors have shown that BM and tumors of transgenic mice contain high number of CD8-positive T cells specific for the melanoma antigen tyrosinase-related protein and showing mostly effector memory phenotype [19] . It was suggested that thereby memory T cells could control disseminated melanoma cells. Mahnke et al. [20] have suggested that the BM microenvironment has special features for the maintenance of tumor dormancy and immunological T-cell memory. Recent publications presented the data confirming this suggestion [21, 22] .
It has to be noted that the publications aimed to find the association between DTCs and memory T cells Exp Oncol 2015 37, 1, 48-52 in BM are limited especially in the clinical setting. Many questions are left to be received the answers to clarify the control of tumor dormancy by host immune reactions. Pantel et al. [1] concluded that the role of the immune system in dormancy control and metastatic progression has not been proved.
In gastric cancer (GC) patients DTCs were also found [23] . Our previous study has shown that DTCs were detected in 51.4% of GC patients with M 0 , and overall survival (OS) of patients with M 0 and DTCs was shorter than that of patients without DTCs (patients in both groups were operated only) (p = 0.0497) [24] . Taking into account these data and the virtual absence of the data concerning association between memory T cells in BM and DTCs we have aimed to find the possible association between presence both of DTCs and CD8-and CD45RO-positive T cells in BM and evaluate the correlation between CD8-and CD45RO-positive T cells in BM and clinical outcome. . All patients were thoroughly informed about the study that was approved by the local ethics committee.
МАTERIALS AND METHODS

Patients
Detection of tumor cells, CD8-and CD45RO-positive T cells in BM. Preoperatively, 2.0-3.0 mL of BM aspirates from the sternum with conventional cautions to avoid the hit of skin epithelial cells into the sample was taken into a heparinized syringe and transferred into a tube "Sarstedt" containing EDTA. After ficoll-hypaque density centrifugation (density, 1.077; Sigma-Aldrich, USA) to isolate the mononuclear cell fraction (1105 g for 20 min), the interphase was washed twice in phosphate-buffered saline (PBS) with removing of erythrocytes (Uti-Lyse Erythrocyte Lysing Reagent, Dako Cytomation, USA), resuspended to a concentration of 570•10 3 cells/30 μL, and cytocentrifuged on glass slides. Specimens were airdried from 12 to 24 hs and stained immediately or stored at -20 °C. Detection of tumor cells (cytokeratin-positive cells) in BM cytospins was performed as presented in [24] .
For the detection of CD8 and CD45RO T cells in BM cytospin preparations were fixed by formol-acetone solution (pH 6.6) in accordance with the instruction. Slides were treated by 0.3% Triton X-100 solution, washed by PBS and blocking of endogenous peroxidase followed by incubation in 3% bovine serum albumin to switch off nonspecific reaction antigen-antibody. Cytospins were incubated with primary monoclonal mouse antibodies against CD8 (clone C8/144B, readyto-use, Dako, Denmark) or with primary monoclonal mouse antibodies against CD45RO (clone UCHL1, Sigma, США) in optimal dilution (1:400) within 1 h. After washing of primary antibodies slides were processed with PolyVueHRP Detection System Components (Diagnostic BioSystems, USA). Visualization of peroxidase activity was provided by staining with DAB (Dako, Denmark). Cytospins were counterstained by solution of Methyl Green (ready-to-use, Dako, Denmark) within 1-2 min. Cytospins were examined by light microscopy (×1000) to detect CD8-and CD45RO-positive T cells.
Tumor hypoxia evaluation by 31 P NMR spectroscopy. Level of tumor hypoxia was assessed with 31 P NMR spectroscopy.
31
P NMR spectra of perchloric acid (PCA) tumor extracts were acquired by means of a highresolution Bruker 400 MHz spectrometer (Widebore Ultrashield, AV-400 electronics, Germany) using a probe of 5 mm inner diameter. All details of method were presented in our earlier publication [27] .
Statistical analysis. All statistical analyses were conducted using the NCSS 2000/PASS 2000 and Prism, version 4.03, software packages. Correlations were analyzed with the Pearson correlation coefficient. The χ 2 test was performed to determine the correlation between the CD8 and CD45RO status of BM and the clinicopathological characteristics. The survival proportion was estimated by using the Kaplan -Meier method and differences in survival were analyzed with the log-rank test. Prognostic values of relevant variables were analyzed by means of the Cox proportional hazards model using hazard ratio and χ 2 test. Two-tailed p values <0.05 were considered statistically significant.
RESULTS AND DISCUSSION
CD8-and CD45RO-positive cells in BM and their correlation with clinical variables. Individual patient data from a total 91 histological confirmed GC patients were included in this study ( Table 1 ). The median age was 62 years. Overall, 80.5 and 81.3% of patients had CD8-and CD45RO-positive T lymphocytes in BM, respectively. There was no association between presence of CD8-or CD45RO-positive T cells in BM and clinicopathological characteristics (Tables 2 and 3) . A marked predominance of the number of patients characterized by the presence of CD8-and CD45RO-positive T cells in BM with M 0 category on patients with CD8-and CD45RO-positive T cells in BM but with M 1 category was not statistically significant.
CD8-and CD45RO-positive cells and DTCs in BM. When DTCs were detected in BM the number of patients with BM that was positive to CD8 and CD45RO T cells were 86.1 and 84.4%, respectively. It was also determined that the number of patients with DTCs in BM with categories M 0 and M 1 and with CD8-and CD45RO-positive T cells in BM was 86.2; 85.7; 85.7 and 80.0%, respectively. It is clearly seen that there is not association between DTCs in BM and pre sence of CD8 and CD45RO T cells lymphocytes in BM. It may be suggested that entering the tumor cells into BM is not linked with the presence and acti vity of CD8 and CD45RO T cells in BM, but most likely CD8 and CD45RO T cells determine the subsequent behavior of DTCs. CD8-and CD45RO-positive cells in BM and hypoxia level in primary tumor. Level of tumor hypoxia assessed by NMR spectroscopy was ranged as follows: if the PME/Pi < 1.0, tumors are characte rized by severe hypoxia, 1.0 < PME/Pi < 1.4 moderate hypoxia, 1.4 < PME/Pi < 2.0 mild hypoxia, and PME/ Pi > 2.0 weak hypoxia (satisfactory oxygenation). The association between presence of CD8-and CD45RO-positive T cells in BM and hypoxia level in tumor was not detected: CD8-positive T cells were found in 81.8% of patients with tumors characterized by severe and moderate hypoxia and 84.2% of patients with tumor characte rized by mild and weak hypoxia, and CD45RO-positive T cells in 86.7 and 82.6%, respectively. Obtained results have shown that tumor hypoxia do not associate with the presence of CD8 and CD45RO T cells in BM and, probably, do not influence their activity. OS of patients with CD8-and CD45RO-positive cells in BM. OS was significantly longer in patients with tumors characterized by the presence of CD8-and CD45RO-positive T cells in BM as compared to patients with the absence of CD8-and CD45RO-positive T cells in BM (log-rank test: p = 0.0343 and p = 0.0235, respectively, Fig. 1 and 2) . It was also determined that OS in patients with DTCs in BM and with presence of CD8-positive T cells in BM was significantly longer in compared with that in patients with DTCs in BM and without CD8-positive T cells in BM (log rank test: p = 0.0226, Fig. 3 ). The same association was found for CD45RO-positive T cells, but it was not statistically significant (log-rank test: p = 0.0537, Fig. 4) . OS in patients with M 0 category was also longer in patients with the presence of CD8-and CD45RO-positive T cells in BM, but this link was not statistically significant (log-rank test: p = 0.0538, Fig. 5 and p = 0.0862, Fig. 6, respectively) .
Separate analysis of OS in patients with M 0 category having DTCs in BM demonstrated that association between the presence of CD8-and CD45RO-positive T cells in BM and OS was also existed but it was not statistically significant (log-rank rest: p = 0.0674 and p = 0.9054, respectively, figures were not presented).
It has to be noted that the association between the presence of CD8-and CD45RO-positive T cells in BM and OS in patients who have been treated with operation alone or adjuvant chemotherapy was not statistically significant. It was found only the tendency for the association between the pre sence of CD8-positive T cells in BM and OS in patients treated with operation alone or with adjuvant chemotherapy (log-rank test: p = 0.0529 and p = 0.0529, respectively, figures were not presented). Obtained results have shown the association between the presence of CD8-and CD45RO-positive T cells in BM and OS of patients, in particular OS was statistically longer in all patients with CD8-and CD45RO-positive T cells in BM than that in patients with CD8-and CD45RO-negative BM. It is very important to note that OS in patients with DTCs in BM and with CD8-positive T cells in BM was significantly longer than that in patients with CD8-negative BM (p = 0.0226).
Median follow-up time was 16.0 (range 0.36-54.4) months from diagnosis for all patients. Overall, 31 patients (34.1%) died during follow-up. In 29 patients (93.5%) death was related to GC. Of these, 78.3% of patients had CD8-and 96.6% of patients had CD45RO-positive T cells in BM. Survival time for patients with the presence of CD8-or CD45RO-positive T cells in BM was 19.6 ± 1.9 months and 20.4 ± 1.5 months, respectively. 
